Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CLGN
$0.619
$
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Next Earnings
2026-02-25
Beta
0.811
Average Volume
Market Cap
Last Dividend
CIK
0001631487
ISIN
IL0004960188
CUSIP
19516R107
CEO
Yehiel Tal
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
57
IPO Date
2018-01-31
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex | BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility REHOVOT, Israel, Feb. 23, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications. BioFlex is engineered to support the biofabrication of advanced tissue models for drug discovery, as well as the development of engineered tissues and transplantable organs. | PRNewsWire | 2026-02-23 07:00:00 |
| CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments | Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapies REHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including patients treated with GLP-1 therapies. The expanding use of GLP-1 therapies for metabolic health and weight management has created a growing population experiencing loss of facial fat, skin laxity, and structural deflation - commonly referred to in the medical community as weight-loss-related facial volume depletion. | PRNewsWire | 2026-02-17 07:00:00 |
| COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING | REHOVOT, Israel, Feb. 5, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,600,000 of the Company's ordinary shares at a purchase price of $1.25 per share in a registered direct offering. In addition, in a concurrent private placement, the Company will issue unregistered series A warrants to purchase up to 1,600,000 ordinary shares and unregistered series B warrants to purchase up to 1,600,000 ordinary shares. | PRNewsWire | 2026-02-05 08:00:00 |
| COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE | Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center scheduled to become operational this quarter and under new commercial leadership for this region Recent developments suggest CollPlant's rhCollagen will have a significant contribution towards innovation in the areas of non-animal alternatives for medical and research Plan for cost reductions and program prioritization in place to extend cash runway REHOVOT, Israel , Nov. 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer, remarked, "CollPlant continued to advance innovation this quarter beyond its core development programs. | PRNewsWire | 2025-11-26 07:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2026-02-23 | 2026-02-23 | View Filing |
| D | 2026-02-17 | 2026-02-17 | View Filing |
| 6-K | 2026-02-17 | 2026-02-17 | View Filing |
| 6-K | 2026-02-06 | 2026-02-06 | View Filing |
| 424B5 | 2026-02-06 | 2026-02-06 | View Filing |
| 6-K | 2026-02-05 | 2026-02-05 | View Filing |
| EFFECT | 2026-01-16 | 2026-01-20 | View Filing |
| F-3 | 2026-01-09 | 2026-01-09 | View Filing |
| 6-K | 2025-12-31 | 2025-12-31 | View Filing |
| SC 13D/A | 2025-11-28 | 2025-11-28 | View Filing |
| 6-K | 2025-11-26 | 2025-11-26 | View Filing |
| 6-K | 2025-11-26 | 2025-11-26 | View Filing |
| SC 13D/A | 2025-11-07 | 2025-11-07 | View Filing |
| 6-K | 2025-10-27 | 2025-10-27 | View Filing |
| SC 13D/A | 2025-10-20 | 2025-10-20 | View Filing |
| 6-K | 2025-10-20 | 2025-10-20 | View Filing |
| 6-K | 2025-10-16 | 2025-10-16 | View Filing |
| SC 13D | 2025-09-30 | 2025-09-30 | View Filing |
| 6-K | 2025-09-30 | 2025-09-30 | View Filing |
| 6-K | 2025-09-15 | 2025-09-15 | View Filing |
| 6-K | 2025-09-12 | 2025-09-12 | View Filing |
| EFFECT | 2025-08-29 | 2025-08-29 | View Filing |
| POS AM | 2025-08-20 | 2025-08-20 | View Filing |
| 6-K | 2025-08-20 | 2025-08-20 | View Filing |
| 6-K | 2025-07-14 | 2025-07-14 | View Filing |
| EFFECT | 2025-07-07 | 2025-07-07 | View Filing |
| 424B3 | 2025-07-03 | 2025-07-03 | View Filing |
| F-1 | 2025-06-17 | 2025-06-17 | View Filing |
| 6-K | 2025-06-09 | 2025-06-09 | View Filing |
| 6-K | 2025-06-04 | 2025-06-04 | View Filing |
| D | 2025-06-04 | 2025-06-04 | View Filing |
| 424B5 | 2025-06-02 | 2025-06-02 | View Filing |
| 6-K | 2025-06-02 | 2025-06-02 | View Filing |
| 6-K | 2025-05-30 | 2025-05-30 | View Filing |
| 6-K | 2025-05-28 | 2025-05-28 | View Filing |
| 6-K | 2025-04-15 | 2025-04-15 | View Filing |
| 20-F | 2025-03-26 | 2025-03-26 | View Filing |
| 6-K | 2025-03-26 | 2025-03-26 | View Filing |
| 6-K | 2025-02-24 | 2025-02-24 | View Filing |
| 6-K | 2025-02-12 | 2025-02-12 | View Filing |
| SC 13G/A | 2025-01-28 | 2025-01-28 | View Filing |
| 6-K | 2024-11-27 | 2024-11-27 | View Filing |
| 6-K | 2024-09-25 | 2024-09-25 | View Filing |
| 6-K | 2024-08-20 | 2024-08-20 | View Filing |
| 6-K | 2024-08-20 | 2024-08-20 | View Filing |
| 6-K | 2024-08-19 | 2024-08-19 | View Filing |
| 6-K | 2024-07-29 | 2024-07-29 | View Filing |
| 6-K | 2024-06-06 | 2024-06-06 | View Filing |
| S-8 | 2024-05-29 | 2024-05-29 | View Filing |
| 6-K | 2024-05-29 | 2024-05-29 | View Filing |
| 6-K | 2024-04-04 | 2024-04-04 | View Filing |
| 20-F | 2024-04-04 | 2024-04-04 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 32.14% | 1.01 | 228 | 0.04 | 0.08 | 57.9 |
| Mean Reversion Strategy | 15.18% | 1.01 | 329 | 0.02 | 0.05 | 40.94 |
| Larry Williams PercentR Strategy | 11.77% | 1.01 | 157 | 0.02 | 0.04 | 37.52 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |